Sylvaine Cotton-Cartot

Sanofi R&D
Chilly, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Randomized Phase III Study of Amcenestrant Plus Palbociclib Versus Letrozole Plus Palbociclib in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Primary Results From AMEERA-5.

Randomized Phase III Study of Amcenestrant Plus Palbociclib Versus Letrozole Plus Palbociclib in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Primary Results From AMEERA-5.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 18, 2024

Joint modeling of tumor dynamics and progression-free survival in advanced breast cancer: Leveraging data from amcenestrant early phase I-II trials.

Joint modeling of tumor dynamics and progression-free survival in advanced breast cancer: Leveraging data from amcenestrant early phase I-II trials.

Journal: CPT: pharmacometrics & systems pharmacology

Published: September 21, 2023

AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2- advanced breast cancer.

AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2- advanced breast cancer.

Journal: Therapeutic advances in medical oncology

Published: August 03, 2021

AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer.

AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer.

Journal: Nature communications

Published: June 18, 2021

Modifications of physical and functional integrity of the blood-brain barrier in an inducible mouse model of neurodegeneration.

Modifications of physical and functional integrity of the blood-brain barrier in an inducible mouse model of neurodegeneration.

Journal: Neuropharmacology

Published: October 31, 2020

High brain distribution of a new central nervous system drug candidate despite its P-glycoprotein-mediated efflux at the mouse blood-brain barrier.

High brain distribution of a new central nervous system drug candidate despite its P-glycoprotein-mediated efflux at the mouse blood-brain barrier.

Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

Published: October 17, 2017

First-in-human trial of the PI3Kβ-selective inhibitor SAR260301 in patients with advanced solid tumors.

First-in-human trial of the PI3Kβ-selective inhibitor SAR260301 in patients with advanced solid tumors.

Journal: Cancer

Published: June 27, 2017

Optimizing pharmacokinetic bridging studies in paediatric oncology using physiologically-based pharmacokinetic modelling: application to docetaxel.

Optimizing pharmacokinetic bridging studies in paediatric oncology using physiologically-based pharmacokinetic modelling: application to docetaxel.

Journal: British journal of clinical pharmacology

Published: July 24, 2014

Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours.

Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 29, 2012

Showing 1-9 of 9

Last Updated: 09/26/2026